AMLX — Amylyx Pharmaceuticals, Inc. stock price, charts and financials

QT90Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
22.67
-0.15-0.66%
OverviewShort InterestFilings
AMLXQT90Amylyx Pharmaceuticals, Inc.·NASDAQ
22.67-0.66%
TA
Loading chart...
Signal & projected range
Earnings miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RARE+3.44%$26.80PGEN-3.18%$7.00ZLAB+1.07%$23.57TRVI-3.84%$17.80PHVS-0.20%$34.84NRIX+1.37%$25.88KLRA+1.71%$18.98MLYS+0.11%$27.38
Snapshot
Index-P/E-EPS (ttm)-2.45Insider Own37.26%Shs Outstand111.19MPerf Week12.36%
Market Cap2.54BForward P/E-EPS next Y-1.34Insider Trans-0.26%Shs Float82.38MPerf Month24.16%
Enterprise Value2.49BPEG-EPS next Q-Inst Own-Short Float14.89%Perf Quarter50.13%
Income-151.98MP/S0.00EPS this Y41.05%Inst Trans-Short Ratio8.94Perf Half Y75.67%
Sales299.00MP/B10.61EPS next Y7.30%ROA-57.49%Short Interest12.27MPerf YTD88.91%
Book/sh-P/C-EPS next 5Y-ROE-52.92%52W High24.44 -7.24%Perf Year178.63%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-66.32%52W Low7.43 205.08%Perf 3Y0.09%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility8.36% 7.10%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM44.70%Oper. Margin0.00%ATR (14)1.40Perf 10Y-
Dividend Ex-DateMar 28, 2018Quick Ratio12.12Sales Y/Y TTM243.68%Profit Margin0.00%RSI (14)68.09Recom2.09
Dividend Gr. 3/5Y-Current Ratio12.12EPS Q/Q11.90%SMA2017.47%Beta1.19Target Price31.50
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA5032.23%Rel Volume1.60Prev Close22.82
Employees136LT Debt/Eq0.02EarningsNov 05SMA20052.01%Avg Volume1.67MPrice22.67
IPO DateJan 07, 2022Option/ShortYes / YesEPS/Sales Surpr.-9.48% -Net Debt/EBITDA0.29Volume2,678,297Change-0.66%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRobert W. Baird$19 → $28
Jul-20-26ReiteratedMizuhoOutperform$21 → $24
Jun-25-26ReiteratedGuggenheimBuy$25 → $40
Jun-08-26ReiteratedH.C. WainwrightBuy$28 → $34
Apr-28-26ReiteratedMizuhoOutperform$19 → $21
Feb-19-26ReiteratedMizuho SecuritiesOutperform$18 → $19
Feb-10-26ReiteratedHC Wainwright & Co.Buy$8.00 → $28
Oct-29-25ReiteratedMizuho SecuritiesOutperform$12 → $16
Oct-16-25ReiteratedRobert W. Baird$10 → $19
Sep-15-25ReiteratedGuggenheimBuy$17 → $25
Latest News
Aug-07-26
Aug-07-2611:28AM
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuildseekingalpha.com
Aug-06-26
Aug-06-2601:14PM
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcriptseekingalpha.com
11:06AM
Amylyx Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
07:00AM
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Resultsbusinesswire.com
Aug-03-26
Aug-03-2603:35PM
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26Benzinga
09:00AM
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026businesswire.com
Jul-20-26
Jul-20-2607:34AM
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $24Benzinga
Jul-03-26
Jul-03-2612:15PM
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com
Jun-25-26
Jun-25-2610:12AM
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40Benzinga
Jun-23-26
Jun-23-2607:06AM
Amylyx Pharma To Present Data From First-In-Human, Dose-Ranging Phase 1 LUMINA Trial Of AMX0114 At ENCALS Meeting 2026Benzinga
Company

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue299087—————
Cost of Goods Sold Incl. D&A138142—————
Gross Profit159-145—————
Selling, General and Administrative Excl. Other18163114—————
Research and Development13590104—————
Other Operating Expense-10142—————
Operating Income-154-153-315—————
Interest Expense
000—————
Unusual Expense
————————
Non-Operating Income (Expense)-6913—————
Net Income Before Taxes-164-145-302—————
Income Taxes
400—————
Consolidated Net Income-166-145-302—————
Net Income From Continuing Operations-166-145-302—————
Net Income-166-145-302—————
EPS (Recurring)-2.44-1.53-4.43—————
EPS (Basic, Before Extraordinaries)-2.44-1.53-4.43—————
EPS (Diluted)-2.45-1.53-4.43—————
EBITDA-160-144-291—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio5.16—2.95—————
Gross Margin53.18—51.72—————
Operating Margin-51.51—-362.07—————
Net Margin-55.52—-347.13—————
Shares Outstanding689568—————
Market Capitalization1,5421,148257—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$27.08$20.81$14.54$8.28$2.01● Close Price0.00M0.99M1.98M2.97M3.96MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mazzariello GinaChief Legal OfficerJul 10 '26Sale17.6115,000264,122179,090Jul 13
Mazzariello GinaChief Legal OfficerJul 09 '26Sale18.3215,000274,746194,090Jul 13
Firestone KarenDirectorMay 21 '26Buy13.513,80051,33866,900May 26
Cohen Joshua BCo-Chief Executive OfficerMar 02 '26Sale14.4829,282424,1203,334,683Mar 04
Klee Justin B.Co-Chief Executive OfficerMar 02 '26Sale14.4729,282423,7603,334,616Mar 04
Bedrosian Camille LChief Medical OfficerMar 02 '26Sale14.586,46194,205169,295Mar 04
FRATES JAMES MChief Financial OfficerMar 02 '26Sale14.527,909114,851165,638Mar 04
Mazzariello GinaChief Legal OfficerMar 02 '26Sale14.526,84499,378134,430Mar 04
Mazzariello GinaChief Legal OfficerFeb 23 '26Sale14.143,41948,352141,274Feb 25
FRATES JAMES MChief Financial OfficerFeb 02 '26Sale14.653,55752,097173,547Feb 04
Cohen Joshua BCo-Chief Executive OfficerFeb 02 '26Sale14.6815,500227,5933,363,965Feb 04
Mazzariello GinaChief Legal OfficerFeb 02 '26Sale14.653,44850,516144,693Feb 04
Klee Justin B.Co-Chief Executive OfficerFeb 02 '26Sale14.6915,500227,6183,363,898Feb 04
Klee Justin B.Co-Chief Executive OfficerJan 16 '26Option Exercise7.572,84721,5523,381,393Jan 20
Cohen Joshua BCo-Chief Executive OfficerJan 16 '26Option Exercise7.572,81821,3323,381,439Jan 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.